2017 American Transplant Congress
Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.
The need for using induction therapy in de novo non-HLA sensitized kidney-transplant patients receiving tacrolimus-based therapy is a matter of debate. The aims of this…2017 American Transplant Congress
Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience.
BACKGROUND AND AIMS: Preexisting donor specific antibodies (DSA) cause acute antibody mediated rejection (AMR), which can be avoided during pre-transplant work up. Diagnosis and management…2017 American Transplant Congress
Novel Biomarkers for Segregating Lung Transplant Rejection Phenotypes.
We sought to investigate biomarkers in BAL fluid and tissue for segregating BOS and RAS chronic rejection phenotypes in lung allografts. We had previously identified…2017 American Transplant Congress
Integrated Magnetic-Electrochemical Exosome (iMEX) Technology to Detect Rejection in Kidney Transplant Recipients.
Transplantation Research Center, Harvard Medical School, Boston; Exosome Diagnostic Inc, Cambridge
Methods for monitoring clinical rejection including increases in serum creatinine and urinary protein excretion may not reflect subclinical rejection. Similarly repeat biopsy may result in…2017 American Transplant Congress
Liver Transplantation Outcomes Using Anti-Thymocyte Globulin Induction in Patients with Autoimmune Hepatitis.
Transplantation Surgery, Virginia Commonwealth University, Richmond, VA
Background: The use of rabbit anti-thymocyte globulin (ATG) induction in high immunological risk patients with autoimmune hepatitis (AIH) could lower the rejection rates after liver…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…2017 American Transplant Congress
Clinical Correlation of Endomyocardial Biopsies Molecular Profiling: Taking Rejection Diagnosis Beyond Histology.
Histology grading of endomyocardial biopsies (EMB), the standard for diagnosing T-cell-mediated (TCMR) and antibody-mediated (ABMR) rejection, has serious issues with reproducibility (Transplantation 94 (11):1172177, 2012)…2017 American Transplant Congress
Immunodominant Donor Specific Antibody Reduction with Proteasome Inhibitor Based Treatment: Clinical Variability and Implications for Long Term Graft Survival.
1University of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati
Proteasome inhibitor (PI) based regimens treat antibody mediated rejection (AMR) at least in part by eliminating donor specific antibody (DSA). iDSA response to PI-based therapy…2017 American Transplant Congress
Pre-Transplant HLA-Specific B Cell Breadth of Reactivity in a Novel Multiplex Bead-Based Assay Predicts Rejection in Kidney Transplant Recipients.
1Northwestern University, Chicago; 2Icahn School of Medicine at Mount Sinai, New York
Introduction: Recipients with broad sensitization to HLA defined by a high percentage of Panel Reactive Antibodies (PRA) are at higher immunologic risk for poor graft…2017 American Transplant Congress
Regulatory T Cells Inhibit Plasmablast Formation and IgG Production by Tempering T Follicular Helper Cell Function.
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA
Background: Donor-specific antibodies (DSA) are an important biomarker for acute rejection, transplant glomerulopathy and late allograft failure in kidney transplantation. Few studies have characterized the…
- « Previous Page
- 1
- …
- 122
- 123
- 124
- 125
- 126
- …
- 172
- Next Page »